Deals Shaping The Medical Industry, February 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
You may also be interested in...
Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108
The latest drug development news and highlights from our FDA Performance Tracker.
First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns
Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.
GSK Makes New Adult Immunization Push, Seeks Reimbursement Changes Following RSV Approvals
From ACIP to Part D to data transparency, GSK has several policy asks as it prepares to launch its new RSV vaccine for older adults. The Pink Sheet spoke with GSK’s vaccine policy lead about the firm’s new data platform and the worrisome US vaccination trends following the Covid pandemic.